title: Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
abstract: 2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.
authors: Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, Johannes Gutenberg University Medical Centre Mainz, Department of Neurology, Langenbeckstrasse 1, D-55131 Mainz, Germany. axel.methner@unimedizin-mainz.de
authors: Axel
authors: A
authors: Methner
authors: Frauke
authors: F
authors: Zipp
mesh_terms: D002986:Clinical Trials as Topic; D000069462:Dimethyl Fumarate; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D024661:Potassium Channels, Inwardly Rectifying / Q000187:drug effects; D015363:Quinolones / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics / Q000502:physiology; D013601:T-Lymphocytes / Q000187:drug effects; D000098854:Kcnj10 Channel
chemical_list: D005650:Fumarates; D007166:Immunosuppressive Agents; D000098854:Kcnj10 Channel; D024661:Potassium Channels, Inwardly Rectifying; D015363:Quinolones; D047888:Receptors, Tumor Necrosis Factor, Type I; C476223:laquinimod; D000069462:Dimethyl Fumarate